Edition:
United Kingdom

Blueprint Medicines Corp (BPMC.OQ)

BPMC.OQ on NASDAQ Stock Exchange Global Select Market

77.53USD
19 Jan 2018
Change (% chg)

$1.14 (+1.49%)
Prev Close
$76.39
Open
$76.12
Day's High
$79.03
Day's Low
$76.12
Volume
96,849
Avg. Vol
183,800
52-wk High
$92.00
52-wk Low
$31.40

Chart for

About

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug... (more)

Overall

Beta: --
Market Cap(Mil.): $2,592.25
Shares Outstanding(Mil.): 39.12
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Blueprint Medicines Prices Public Offering Of 3.70 Mln Shares At $81.00/Share

* BLUEPRINT MEDICINES ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK

13 Dec 2017

BRIEF-Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock

* BLUEPRINT MEDICINES ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK

11 Dec 2017

BRIEF-Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285

* Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes

10 Nov 2017

BRIEF-Thermo Fisher enters agreement with Blueprint Medicines​

* Thermo Fisher Scientific Inc - ‍ expanded development of Oncomine Dx Target Test by entering into an agreement with Blueprint Medicines Corporation​

31 Oct 2017

BRIEF-Blueprint Medicines Q3 loss per share $0.96

* Blueprint Medicines reports third quarter 2017 financial results

31 Oct 2017

BRIEF-Blueprint Medicines Q2 loss per share $0.86

* Blueprint Medicines reports second quarter 2017 financial results

02 Aug 2017

BRIEF-Blueprint Medicines to evaluate advance disease discovery program opportunities

* Blueprint Medicines to evaluate opportunities to advance rare disease discovery program in fibrodysplasia ossificans progressiva following discontinuation of collaboration with Alexion

27 Jul 2017

Competitors

Earnings vs. Estimates